Search Results - "Birrell, Matt R"

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma by Horwitz, Steven M., Feldman, Tatyana A., Hess, Brian T., Khodadoust, Michael S., Kim, Youn H., Munoz, Javier, Patel, Manish R., Phillips, Tycel J., Smith, Stephen D., Smith, Sonali M., Wilcox, Ryan A., Birrell, Matt R., Leeds, Janet M., Conley, Pamela B., Michelson, Glenn C., Coffey, Gregory P., Curnutte, John T., Hamlin, Paul A.

“…Background: SYK and JAK signaling pathways may be critical mediators in the pathogenesis of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma…”
Get full text

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab by Smith, Stephen D., Munoz, Javier, Stevens, Don, Smith, Sonali M., Feldman, Tatyana A., Ye, J Christine, de Vos, Sven, Hess, Brian T., Miller, Carole B., Khatcheressian, James L., Birrell, Matt R., Leeds, Janet M., Coffey, Gregory P., Conley, Pamela B., Michelson, Glenn C., Curnutte, John T., Hamlin, Paul A.

“…Background: Despite recent advances, follicular lymphoma (FL) remains incurable for most patients. Relapsed/refractory (r/r) FL is associated with decremental…”
Get full text

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma by Horwitz, Steven M., Feldman, Tatyana A., Hess, Brian T., Khodadoust, Michael S, Kim, Youn H., Munoz, Javier, Patel, Manish R, Phillips, Tycel J., Smith, Stephen D., Smith, Sonali M., Wilcox, Ryan A., Steele, Andrew, Pandey, Anjali, Birrell, Matt R, Leeds, Janet M., Conley, Pamela B., Michelson, Glenn, Coffey, Gregory P., Curnutte, John T, Hamlin, Paul A.

“…Background: Pre-clinical data suggest a role for SYK and JAK signaling pathways as oncogenic drivers in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell…”
Get full text